国恩股份 成立于2000年，是一家以 大化工 和 大健康 为两大核心产业的上市公司， 于2015年在深交所上市。 大健康领域方面 ，公司控股胶原领域上市公司 东宝生物 ，通过明胶、代血浆明胶、胶原蛋白、空心胶囊、双蛋白膳食纤维、美妆产品等在"医、美、 健、食"的广泛应用，深入布局大健康产业细分领域。 【DT新材料】 获悉， 2月3日， 国恩股份 公告称，公司已确定本次H股发行的最终价格为每股36.00港元， 公司本次发行的H股将于2026年2月4日 在香港联交所主板挂牌并开始上市交易！ 此前，2025年5月25日， 国恩股份 发 布公告称， 公司审议通过发行H股股票并在香港联交所主板挂牌上市的议案， 计划通过发行境外上市外资股 （H股）股票， 打造国际化资本运作平台，加快构建国内国际双循环格局。 此外， 12月3日， 国恩股份 公告称"年产20000㎡航空级亚克力玻璃项目"已获批备案 ，投资5.6亿元，落户于青岛总部生产基地。据悉，航空级交 联聚甲基丙烯酸甲酯亚克力玻璃（CPMMA）通过化学交联形成三维网状结构，在保持93%以上高透光率的同时，具备更优异的机械强度、耐热性与 耐候性，是制造飞机风挡、座舱盖等航 ...

Core Viewpoint - Guoen Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operation platform and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1] Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and is headquartered in Qingdao, focusing on two core industries: large chemicals and health [1] - The company operates a vertically integrated industrial platform and implements a "one body, two wings" development strategy, forming a cluster of new chemical materials [1] - The company has a strong presence in the health sector through its subsidiary Dongbao Biological, which produces a variety of products including gelatin and collagen [1] Group 2: Chemical Industry Segment - The large chemical segment generated revenue of 17.369 billion yuan in 2024, accounting for 90.38% of total revenue, with a year-on-year growth of 11.62% [3] - The company has established long-term stable partnerships with major clients such as Hisense, Gree, TCL, Huawei, BOE, and CATL [3] - Current production capacities include 1.08 million tons for organic polymer modified materials, 400,000 tons for organic polymer composite materials, and 900,000 tons for green petrochemical materials [4] Group 3: Product Development and Market Strategy - The company is enhancing its market share in the new energy vehicle sector by improving the performance of modified materials such as PP, PC, ABS, and PA [2] - In the energy storage battery sector, the company is advancing the application of flame-retardant and anti-explosion materials [2] - Future plans include expanding production capacities for polystyrene and developing new products like high-performance polyolefin elastomers and biodegradable materials [5] Group 4: Financial Performance - In 2024, the health segment generated revenue of 885 million yuan, accounting for 4.6% of total revenue [5] - Overall, the company achieved a total revenue of 19.22 billion yuan in 2024, a year-on-year increase of 10.21%, with a net profit of 676 million yuan, up 45.18% [5] - The first quarter of 2025 reported total revenue of 4.412 billion yuan, a slight decrease of 0.23% year-on-year, with a net profit of 111 million yuan, down 9.79% [6]

Core Viewpoint - Guoen Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operation platform and accelerate the construction of a dual circulation pattern in the domestic and international markets [1] Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and is headquartered in Qingdao, focusing on two core industries: large chemicals and health [1] - The company operates a vertically integrated industrial platform and implements a "one body, two wings" development strategy, forming a chemical new materials industry cluster [1] - The company has a strong presence in the health sector through its subsidiary Dongbao Biological, which specializes in gelatin and collagen products [1] Group 2: Chemical Sector Performance - In the new energy vehicle sector, the company is increasing market share in modified materials such as PP, PC, ABS, PA, and PMMA [2] - The company has a current production capacity of 1.08 million tons for organic polymer modified materials, 400,000 tons for organic polymer composite materials, and 900,000 tons for green petrochemical materials [2] - In 2024, the chemical sector achieved revenue of 17.369 billion yuan, accounting for 90.38% of total revenue, with a year-on-year growth of 11.62% [3] Group 3: Health Sector Performance - The health sector, led by Dongbao Biological, has an annual gelatin production capacity of 13,500 tons and a future capacity of 70 billion capsules [4] - In 2024, the health sector generated revenue of 885 million yuan, representing 4.6% of total revenue [4] Group 4: Overall Financial Performance - In 2024, Guoen Co., Ltd. reported total revenue of 19.220 billion yuan, a year-on-year increase of 10.21%, with a net profit of 676 million yuan, up 45.18% year-on-year [4] - The company reported a slight decline in revenue and net profit in Q1 2025 compared to the same period last year, with total revenue of 4.412 billion yuan, down 0.23% year-on-year [4]